Reliance Global Group Inc Dossier
|
SectorFinancials IndustryInsurance Brokers Beta (adjusted)1.47 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $2.35Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $1.9M Enterprise Value $4.2M Shares Outstanding 820.9K diluted Next Earnings Date13 Nov 2026 Last ex-dividend30 Oct 2025 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Reliance Global Group, Inc. (NASDAQ: EZRA) is undergoing a significant strategic transition, shifting from a traditional insurance brokerage model to a diversified technology-driven holding company under its Scale51 framework. While the company has successfully streamlined its balance sheet through non-core asset divestitures and regained compliance with Nasdaq's minimum bid price rule via a 1-for-40 reverse split, its new strategic ventures in post-quantum cybersecurity (Enquantum) and life sciences (LifeSci Global Group) are early-stage and currently loss-making. Given the ongoing operational losses and potential dilution from its $50 million equity line of credit, a Hold recommendation is warranted until these high-growth technology investments demonstrate clear commercial traction and path to profitability. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.1820% The early-stage technology and life sciences investments fail to achieve commercial milestones, resulting in write-downs. Core insurance commission revenue continues to decline due to previous divestitures, and heavy utilization of the equity line of credit causes severe shareholder dilution, putting downward pressure on the stock price. Base CaseCentral scenario $3.5055% Reliance Global Group continues to execute its transition, gradually increasing its stake in Enquantum and stabilizing its core insurance commission revenue. Operating losses narrow slowly, and the company relies on its equity line of credit for funding, resulting in moderate dilution. The stock trades in line with micro-cap technology holding companies. Bull CaseUpside scenario $7.0025% The Scale51 strategy successfully accelerates commercialization of Enquantum's post-quantum cryptography and LifeSci Global's radiopharmaceutical platforms, driving rapid high-margin revenue growth. Organic growth in the remaining InsurTech platform (RELI Exchange 2.0) accelerates, and the company achieves operating profitability, leading to significant multiple expansion. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |